Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Synthetic MR ABSYNMF 63 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates SYNMF with a GF Score™ of 63/100 and a GF Value™ of $1.21. The stock has 3 warning signs investors should review. Among 564 Healthcare Providers & Services companies, Synthetic MR AB ranks better than 90.96% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Synthetic MR AB's Debt-to-Equity or its related term are showing as below:
SYNMF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 0.04
Current: 0.03
During the past 13 years, the highest Debt-to-Equity Ratio of Synthetic MR AB was 0.04. The lowest was 0.00. And the median was 0.03.
SYNMF's Debt-to-Equity is ranked better than 90.96% of 564
companies
in the Healthcare Providers & Services industry
Industry Median: 0.42
vs SYNMF: 0.03
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Synthetic MR AB Debt-to-Equity Related Terms
Synthetic MR AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Synthetic MR AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SYNMF vs VEEV, BTSG, HQY: Debt-to-Equity Comparison
For the Health Information Services subindustry, Synthetic MR AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synthetic MR AB Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Synthetic MR AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Synthetic MR AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Synthetic MR AB (SYNMF) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Synthetic MR AB and its competitors. According to the industry distribution chart, Synthetic MR AB ranks #51 out of 564 companies in the Healthcare Providers & Services industry, placing it in the top 9%.
Is Synthetic MR AB's Debt-to-Equity too high?
Synthetic MR AB's current Debt-to-Equity is 0.00. Based on the distribution chart, Synthetic MR AB ranks #51 out of 564 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Synthetic MR AB has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Synthetic MR AB's Debt-to-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Synthetic MR AB ranks #51 out of 564 companies for Debt-to-Equity. This places Synthetic MR AB in the top 9% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.42, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Synthetic MR AB and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synthetic MR AB's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synthetic MR AB stock overvalued right now?
Synthetic MR AB (SYNMF) has a current Debt-to-Equity of 0.00. The stock's GF Value™ is $1.21, compared to a current price of $0.19 — trading 84.6% below its estimated fair value. The current Debt-to-Equity is 0.00. Synthetic MR AB's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Synthetic MR AB (SYNMF), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synthetic MR AB (SYNMF) Overvalued in 2026?
Based on GuruFocus' analysis, Synthetic MR AB stock appears to be undervalued.
The current stock price of $0.19 is trading 84.6% below its estimated GF Value™ of $1.21.
Key valuation signals for SYNMF:
Debt-to-Equity: 0.00
GF Value™: $1.21 vs. price of $0.19 (84.6% below fair value)
No single metric tells the full story. See the SYNMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synthetic MR AB develops and markets software solutions that improve the efficiency of neuroimaging processes and diagnostic accuracy. SyntheticMR's SyMRI solution measures the brain's absolute tissue properties and generates multiple contrast-weighted images, performs automatic segmentation of biomarkers, and delivers quantitative data in a single rapid examination. Combinostics offers the AI-driven cNeuro product family, which helps clinicians make a difference in the lives of patients with neurological diseases. Geographically, the group operates in America, Europe, and APAC. The majority of its revenue is generated from Europe.
63GF Score
Get the complete analysis for SYNMF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SYNMF has been successfully added to your 
